On August 4, 2022, Zymeworks Inc. announced that the Company's board of directors appointed Mr. Neil Klompas, age 50, as President of the Company, effective August 4, 2022. Mr. Klompas currently serves as the Company's Chief Operating Officer, and will continue in the role of Chief Operating Officer following his appointment as President of the Company. Mr. Klompas succeeds Mr. Kenneth Galbraith in the role of President of the Company.

Following Mr. Klompas's appointment, Mr. Galbraith will continue in the role of Chair of the Board and Chief Executive Officer. Mr. Klompas joined Zymeworks in March 2007 and has served as its Chief Operating Officer since January 2022, its Chief Financial Officer from December 2007 to February 2022, and also as its Executive Vice President, Business Operations from September 2019 to January 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances.

Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG's Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia.

Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia.